In addition to my previous post on CETP inhibitors, i here present patent status of some companies who involved in development of CETP inhibitor class of drugs.
The method of using CETP inhibitors for treating atherosclerosis and cardiovascular conditions, were known before 1993 .
The companies which are involved in development of CETP inhibitors are Japan Tabacco, Pfizer, Merck, Novartis, Bayer & Searle. Among these companies Merck has now presented positive outcome of Phase III results
Pfizer has many patent applications on combination of CETP inhibitors with other class of cardiovascular drugs like statins and Searle has some patent applications on combination of CETP inhibitors with Nicotinic acid, Fibric acid derivatives.
Torcetrapib’s product patent is WO 2000/017165; Anacetrapib’s product patent is US 7,652,049 and Dalcetrapib’s product patent is WO 1998/035937
A Complete list of Patents on CETP inhibitors is available here